NCT06559176: An ongoing trial by Prime Medicine, Inc.
This trial is ongoing. It must report results 4 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06559176 |
|---|---|
| Title | A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Modified Ex Vivo Using Prime Editing (PM359) in Participants With Autosomal Recessive Chronic Granulomatous Disease Due to Mutations in the NCF1 Gene |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 17, 2024 |
| Completion date | Jan. 31, 2030 |
| Required reporting date | Jan. 31, 2031, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 20, 2026 |
| Days late | None |